Answers are grounded in this paper and cite their sources.
The pharmaceutical market has undergone radical changes, including markedly increased prices for rare-disease drugs. The revenue generated by such products raises questions about whether the Orphan Drug Act should be reformed to better align with the needs of patients.
No takes yet. Share an insight, caveat, or question.
Sarpatwari et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: